Rescriptor (Delavirdine) for HIV

Overview
Rescriptor is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in combination with at least two other antiretroviral medications. Rescriptor is not recommended to be taken alone as monotherapy for HIV. Rescriptor is also referred to by its drug name, Delavirdine, and by the abbreviation DLV.

Rescriptor is an antiviral medication of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Rescriptor is believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Rescriptor is taken three times daily. Rescriptor comes in tablet form.

Side effects
The FDA-approved label for Rescriptor lists common side effects including rash, diarrhea, nausea, headache, fatigue, and changes in body fat shape or location. Rare but serious side effects listed for Rescriptor include severe skin reactions, severe lower back pain, and loss of bowel or bladder control.

For more details about this treatment, visit:

Rescriptor – RxList

Overview of HIV Treatments – AIDS.gov